Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) is actively cooperating with India’s regulatory authorities on the registration of Sputnik Light (the one-shot vaccine based on human adenovirus serotype 26, the first component of the Sputnik V) as a standalone vaccine and a universal booster and expects it to be authorised in the country soon.

A major partner of RDIF, Dr Reddy’s Laboratories, has conducted additional clinical trials of Sputnik Light in India. Positive data from these trials have also been presented to India's regulator. 

Sputnik Light has proven to be safe and highly effective by real-world vaccination data. In particular, the vaccine has demonstrated efficacy of between 78.6-83.7% among the elderly as confirmed by the Ministry of Health of Buenos Aires, Argentina. Paraguay’s Ministry of Health also found Sputnik Light to be 93.5 per cent effective during the country’s ongoing vaccination campaign.

Results of a separate joint clinical trial of a combination of Sputnik Light with the AstraZeneca vaccine have demonstrated that it induces strong immunity and has a high safety profile. 

RDIF has also provided India’s regulator with documents for registration of Sputnik M – the vaccine for adolescents aged 12-17. Russia's Health Ministry registered Sputnik M on November 24, 2021. It has become a new member of the Sputnik vaccines family and is offered to international markets joining Sputnik V and Sputnik Light. 

Subject to the positive decision of India’s authorities, Sputnik M could become the first registered vaccine for adolescents in the country and make an important contribution to protecting the younger population.